Send to

Choose Destination
See comment in PubMed Commons below
J Blood Med. 2010;1:221-5. doi: 10.2147/JBM.S7158. Epub 2010 Sep 10.

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.

Author information

  • 1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.


Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included.


dasatinib; outcomes; resistant CML

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk